Study record · Cerebrolysin
Cerebrolysin in mild-to-moderate Alzheimer's disease: meta-analysis
Short-term cognitive and global signals favoured Cerebrolysin; cognitive effect at 6 months was not statistically significant while global change remained.
Key result
Short-term cognitive and global signals favoured Cerebrolysin; cognitive effect at 6 months was not statistically significant while global change remained significant.
Study details
Study designMeta-analysis of randomized double-blind placebo-controlled trials
PhaseNot applicable
PopulationPatients with mild-to-moderate Alzheimer disease
Sample size6 RCTs
RouteIntravenous
Regimen / exposure30 mL/day in eligible trials
DurationTypically 4-week treatment with follow-up
ComparatorPlacebo
Primary endpoint / questionCognitive function/global clinical change
Safety resultSafety criteria comparable to placebo in included AD trials.
Key limitationsOlder trials; potential sponsor/author involvement; results differ across cognitive vs global endpoints and from stroke evidence.
Registry / identifierPMID 25832905